Wolverine Trading, LLC Brainstorm Cell Therapeutics Inc. Call Options Transaction History

Wolverine Trading, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 23, 2023	BUY	$2.0 - $3.2 $30,000 - $48,000	15,000 Added 55.76%	41,900 $86,000
Q1 2023 May 15, 2023	SELL	$1.43 - $3.3 $2,574 - $5,940	-1,800 Reduced 6.27%	26,900 $67,000
Q4 2022 Feb 14, 2023	SELL	$1.37 - $4.42 $40,552 - $130,832	-29,600 Reduced 50.77%	28,700 $47,000
Q3 2022 Nov 14, 2022	BUY	$2.55 - $4.42 $148,665 - $257,686	58,300 New	58,300 $243,000
Q2 2022 Aug 15, 2022	SELL	$2.71 - $3.6 $29,810 - $39,600	-11,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.92 - $4.19 $32,120 - $46,090	11,000 New	11,000 $37,000
Q2 2021 Aug 06, 2021	SELL	$3.01 - $4.01 $71,939 - $95,839	-23,900 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$3.46 - $7.88 $6,574 - $14,972	-1,900 Reduced 7.36%	23,900 $89,000
Q4 2020 Feb 12, 2021	BUY	$3.99 - $17.73 $102,942 - $457,434	25,800 New	25,800 $119,000
Q4 2017 Feb 14, 2018	SELL	$2.96 - $4.42 $31,968 - $47,736	-10,800 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$3.98 - $4.36 $42,984 - $47,088	10,800	10,800 $44,000

10.8M

160K

30.5K

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $82.8M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.